Edge Rewrite
location Source code View original
// request.cf · coarse context

A page that knows where it met you.

Only coarse request metadata is shown. This demo does not display or persist visitor IP addresses.

Country
US
Cloudflare location
CMH
Connection
HTTP/2
Language
Not provided

Ray ID: a2a97cfbfcbc89da

Jump to content

Linepemat

Add links
From Wikipedia, the free encyclopedia

Linepemat
Clinical data
Other names3-(2,3-Difluorophenoxy)azetidine
Routes of
administration		Oral[1]
Drug classNootrope
Identifiers
  • 3-(2,3-difluorophenoxy)azetidine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC9H9F2NO
Molar mass185.174 g·mol−1
3D model (JSmol)
  • C1C(CN1)OC2=C(C(=CC=C2)F)F
  • InChI=1S/C9H9F2NO/c10-7-2-1-3-8(9(7)11)13-6-4-12-5-6/h1-3,6,12H,4-5H2
  • Key:TXTVXNRODZFMEX-UHFFFAOYSA-N

Linepemat (INNTooltip International Nonproprietary Name), also known as 3-(2,3-difluorophenoxy)azetidine, is a drug described as a "nootrope".[2][3][4] It has been found to produce hyperlocomotion in rodents as well as to dose-dependently reverse the hypolocomotion induced by the monoamine depleting agent tetrabenazine in rodents.[3] The drug was patented by Integrative Research Laboratories (IRL) in January 2025 with the application of treatment of apathy[3][4] and its INNTooltip International Nonproprietary Name was registered in January 2026.[2] IRL is developing a drug with the developmental code name IRL757 for treatment of apathy in Parkinson's disease and neurodegenerative disorders.[1][5][6][7][8][9] As of January 2026, IRL757 is in phase 1/2 clinical trials for Parkinson's disease and phase 1 trials for neurodegenerative disorders, having entered phase 1/2 trials by December 2025.[1] Linepemat is very similar in chemical structure to pirepemat (IRL752), another nootropic drug candidate.[3]

See also

[edit]

References

[edit]
  1. 1 2 3 "IRL 757". AdisInsight. Springer Nature Switzerland AG. 8 January 2026. Retrieved 19 February 2026.
  2. 1 2 "Proposed INN: List 134 International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 39 (4): 1217–1218. 2025.
  3. 1 2 3 4 WO 2025/008506A1, Waters N, "3-(2,3-difluorophenoxy)azetidine, or a pharmaceutically acceptable salt thereof, for use in the treatment and/or prevention of pathological apathy", published 5 July 2024, assigned to Current Assignee Integrative Research Laboratories Sweden AB
  4. 1 2 WO 2025/008504, Kazačonok G, Ekawa B, Fernandez A, Buksa M, Nguyen L, Waters N, "Pharmaceutically acceptable salts of 3-(2,3-difluorophenoxy)azetidine and uses thereof", published 9 January 2025, assigned to Current Assignee Integrative Research Laboratories Sweden AB
  5. ↑ "Delving into the Latest Updates on IRL-757 with Synapse". Synapse. 8 May 2025. Retrieved 19 February 2026.
  6. ↑ "IRL-757 Drug Profile". Ozmosi. 1 January 1900. Retrieved 19 February 2026.
  7. ↑ Lobo A (30 May 2025). "Apathy treatment IRL757 found safe in multiple doses". Parkinson's News Today. Retrieved 19 February 2026.
  8. ↑ Lobo A (3 November 2025). "New Parkinson's drugs targeting apathy, falls, are advancing". Parkinson's News Today. Retrieved 19 February 2026.
  9. ↑ Turner D (30 May 2024). "Drug candidate for apathy enters Phase I trials". Drug Discovery World (DDW). Retrieved 19 February 2026.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Linepemat&oldid=1361892088"